ALTIMMUNE, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
ALTIMMUNE, INC. (ALT) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$18.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-06
- ALTIMMUNE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$18.65M.
- ALTIMMUNE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$19.96M.
- ALTIMMUNE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2016 was $71.76M.
- ALTIMMUNE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2015 was -$1.15M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$18.65M 10-K · filed 2026-03-06 |
| 2024-12-31 | -$19.96M 10-K · filed 2026-03-06 |
| 2016-12-31 | $71.76M 10-K · filed 2017-03-14 |
| 2015-12-31 | -$1.15M 10-K · filed 2017-03-14 |
| 2014-12-31 | -$3.36M 10-K · filed 2017-03-14 |
| 2013-12-31 | -$3.96M 10-K · filed 2016-03-11 |
| 2012-12-31 | -$1.60M 10-K · filed 2015-03-11 |
| 2011-12-31 | -$1.29M 10-K · filed 2014-03-11 |
| 2010-12-31 | -$11.85M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |